Anthem and Resurgens sign agreement on clinical data integration
The agreement also includes initiatives to improve digital connectivity for minimising administrative burdens, enhancing processes, and providing patient-centred care.
Resurgens patients under Anthem health plans can benefit from improved health outcomes.
Comprising nearly 100 physicians in the Atlanta metro area, Resurgens provides patient-centred orthopaedic and spine care to the residents of Georgia and the southeastern region.
Resurgens Orthopaedics chairman Raj Bhole said: 'We are excited to continue our valued partnership with Anthem Blue Cross and Blue Shield of Georgia.
'With 25 office locations, Resurgens Orthopaedics is able to provide Anthem members convenient access to high-quality musculoskeletal care and sub-speciality trained physicians in the communities where they live and work.'
Resurgens offers specialised expertise and experience in joint replacement, sports medicine, trauma care, and orthopaedic surgery.
Anthem Blue Cross and Blue Shield president Robert Bunch said: 'Our continued partnership with Resurgens Orthopaedics reinforces our commitment to complete musculoskeletal care for our members.
'Resurgens Orthopaedics shares our dedication to whole health and serving members across their health journey as seen in their comprehensive care offerings from injury diagnosis and treatment to rehabilitation and imaging services.'
Last month, nonprofit healthcare provider Inova signed a multi-year agreement with Anthem Blue Cross and Blue Shield in Virginia to continue providing healthcare service access for plan members of Anthem.
In October the previous year, Vera Whole Health partnered with Anthem Blue Cross and Blue Shield in Connecticut to introduce an advanced primary care model in Hartford.
"Anthem and Resurgens sign agreement on clinical data integration" was originally created and published by Hospital Management, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
This Cannabis Stock Just Transformed Into a Bitcoin Treasury Play. Should You Buy Shares Now?
It seems that companies whose products and services are not finding takers in the current market are pivoting at the drop of a hat to become Bitcoin (BTCUSD) treasury companies. While the most prominent among them has been the Michael Saylor-led MicroStrategy (MSTR), recently, two biotech companies have also 'rebranded' their business operations to load up on the world's largest cryptocurrency. Among the latest companies to join this bandwagon is cannabis company KindlyMD (NAKA). Valued at a market cap of $90 million, KindlyMD's shares have surged an impressive 742% in the year to date. More News from Barchart Trade the Warren Buffett Rally in UnitedHealth Stock With This High-Reward, Low-Risk Options Strategy Apple Expects $1.1 Billion Tariff Hit in 4th Quarter After $800 Million Q3 Hit; CEO Tim Cook Warns 'Many Factors That Could Change' Cathie Wood Is Buying BLSH Stock After the Bullish IPO. Should You? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. About KindlyMD Founded in 2019, KindlyMD is a Utah-based healthcare provider that specializes in alternative pain management, including through medicinal cannabis use. Its licensed clinicians integrate cannabis therapy into holistic care plans, positioning the company as one of the largest Qualified Medical Providers (QMPs) within Utah's regulated medical cannabis framework. But this is all set to go up in smoke as the company has been acquired by Bitcoin-centric investment firm Nakamoto Holdings. After the merger, the combined company will operate with the KindlyMD name and with the ticker symbol NAKA. The whole transaction generated $540 million in gross proceeds through a private placement in public equity (PIPE) financing, with a $200 million convertible note also closed. Thus, with a $740 million war chest, the company aspires to acquire 1 million BTC. Commenting on the deal, CEO David Bailey said, 'Our vision is for the world's capital markets to operate on a Bitcoin standard. Today's merger represents the beginning of that journey for our company.' Bailey will continue to remain the CEO of the merged entity. Co-founder of KindlyMD and ex-CEO Tim Pickett was also upbeat about the deal, saying, 'We are thrilled to officially close our merger with Nakamoto. We've built KindlyMD on operational and innovative excellence, and we are now extending that same principle to our capital strategy. Bitcoin gives us the ability to preserve value with the same integrity we apply to delivering care.' So, that begs the question: Is NAKA stock a viable investment option now? KindlyMD Posts Widening Losses, Declining Revenues KindlyMD reported revenues of $408,527 in Q2 2025, down 36.1% from the previous year, while net losses widened dramatically to $2.4 million from $1.3 million in the year-ago period. Operational losses also increased, coming in at $2.4 million compared to just over $1 million in the same period a year ago. Net cash outflow from operating activities widened to $2.8 million from $1.1 million in the year-ago period as the company closed the quarter with a cash balance of $6.02 million. This was higher than its total debt levels of $432,978. The Bottom Line After the merger, KindlyMD and NAKA stock look like little more than a passing fad. Just a company that is hoping to take advantage of the Bitcoin treasury momentum as a trade, with no solid operational plans. Thus, avoiding NAKA shares would be a wise choice on the part of investors. On the date of publication, Pathikrit Bose did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Wall Street Journal
3 hours ago
- Wall Street Journal
RFK Jr.'s Misguided War on mRNA
Covid vaccine mandates and a lack of transparency by public-health experts produced many unintended effects—or what scientists call 'off target' responses. One is a political turn against mRNA technology that could damage U.S. innovation and pandemic preparedness. The Health and Human Services Department recently scrapped 22 mRNA-related vaccine investments. 'These vaccines fail to protect effectively against upper respiratory infections like COVID and flu,' Secretary Robert F. Kennedy Jr. said. 'We're shifting that funding toward safer, broader vaccine platforms that remain effective even as viruses mutate.'
Yahoo
4 hours ago
- Yahoo
Do Wall Street Analysts Like Solventum Stock?
With a market cap of $12.4 billion, Solventum Corporation (SOLV) is an independent healthcare company that develops, manufactures, and markets innovative solutions to meet critical patient and customer needs worldwide. Its business spans four segments: Medsurg; Dental Solutions; Health Information Systems; and Purification and Filtration, serving healthcare providers through direct sales, distribution, and digital platforms. Shares of the Maplewood, Minnesota-based company have outperformed the broader market over the past 52 weeks. SOLV stock has increased 21.4% over this time frame, while the broader S&P 500 Index ($SPX) has gained 16.4%. However, shares of the company have risen 8.1% on a YTD basis, lagging behind SPX's 9.7% return. More News from Barchart Lyft Generates Huge FCF Margins - LYFT Stock Is Too Cheap Trade the Warren Buffett Rally in UnitedHealth Stock With This High-Reward, Low-Risk Options Strategy Powell, Trump Talks and Other Can't Miss Items this Week Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. Looking closer, Solventum stock has also outpaced the Health Care Select Sector SPDR Fund's (XLV) 10.8% decrease over the past 52 weeks. Shares of Solventum rose 2% on Aug. 7 after the company reported Q2 2025 adjusted EPS of $1.69 and revenue of $2.2 billion, above Wall Street forecasts. Growth was driven largely by its MedSurg segment, where sales rose 4.8% to $1.2 billion, reflecting robust demand for wound care and surgical sterilization products, alongside lower expenses. Additionally, management raised its full-year adjusted EPS guidance to $5.80 - $5.95, as easing U.S.-China tariff risks reduced expected headwinds. For the fiscal year ending in December 2025, analysts expect SOLV's adjusted EPS to decline 11.9% year-over-year to $5.90. The company's earnings surprise history is mixed. It topped the consensus estimates in three of the last four quarters while missing on another occasion. Among the 13 analysts covering the stock, the consensus rating is a 'Moderate Buy.' That's based on four 'Strong Buy' ratings, eight 'Holds,' and one 'Strong Sell.' This configuration is more bullish than three months ago, with one 'Strong Buy' rating on the stock. On Aug. 8, Piper Sandler increased its price target on Solventum to $94 while maintaining an 'Overweight' rating. As of writing, the stock is trading below the mean price target of $87.12. The Street-high price target of $103 implies a modest potential upside of 44.2% from the current price levels. On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
